Off-market insider buying at IMV (IMV)

Off-market insider buying at IMV (T:IMV)

Fonds de solidarit? FTQ, a 10% Holder, acquired 1,428,571 Common Shares on a direct ownership basis at a price of US$1.75 through a prospectus or prospectus exempt offering on July 20th, 2021. The insider also acquired 1,071,429 Warrants with an exercise price of US$2.100 for 60 months. This represents a $3,182,499 investment into the company's shares and an account share holdings change of 27.9%.

IMV is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company's platform, DPX. The Company's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.